Risk adjusted net present value: What is the current valuation of Medivir’s Fostroxacitabine Bralpamide Hydrochloride?

Fostroxacitabine Bralpamide Hydrochloride is a small molecule commercialized by Medivir, with a leading Phase II program in Hepatocellular Carcinoma.

Risk Adjusted Net Present Value: What is the current valuation of Celltrion’s Aflibercept Biosimilar.

Share this article The revenue for Aflibercept Biosimilar. is expected to reach an annual total of $233 mn by 2039 globally based off GlobalData’s Revenue

November 19, 2023

Dermavant’s PhIII eczema data; Oxford’s Nipah vaccine; Inventiva’s €25M lifeline

Dermavant reported new Phase III data for its atopic dermatitis cream Vtama on Thursday morning, saying more than 80% of participants across two studies saw

January 12, 2024

12 Best Practices For Avoiding A Costly Coding Mistake

Hilton Hudson, MD, FACS, and CEO of HPC International In May 2022, a California doctor was sentenced to nearly eight years in prison for his involvement in

October 18, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.